Streptomycin accumulation in susceptible and resistant strains of Escherichia coli and Pseudomonas aeruginosa.
Streptomycin accumulation by susceptible strains of Escherichia coli and Pseudomonas aeruginosa has been shown to be prevented or inhibited by inhibitors of electron transport, sulfhydryl groups and protein synthesis, and agents that uncouple oxidative phosphorylation. Streptomycin is recovered from cells in an unchanged form and is intracellularly concentrated above extracellular concentrations. Accumulation kinetics are multiphasic; an initial phase which cannot be prevented by the above inhibitors is unable to cause inhibition of cell growth or loss of cell viability. Prevention of further phases of uptake does prevent these events. Inhibitor-susceptible accumulation is time dependent and begins almost immediately upon exposure of cells to streptomycin. Streptomycin accumulation remains energy dependent even when cells are losing acid-soluble [(3)H]adenine, presumably through loss of permeability control. These results demonstrate that streptomycin accumulation necessary for inhibition of cell growth or cell death requires energy and is not a process of diffusion or secondary to membrane leakage. Streptomycin accumulation in ribosomally resistant mutants of E. coli and P. aeruginosa is similar in that both energy-independent and energy-dependent accumulation can be demonstrated. The total energy-dependent accumulation is, however, significantly lower than that in streptomycin-susceptible cells due to the absence of an additional energy-dependent phase of accumulation, which seems dependent on ribosomal binding of streptomycin. Ribosomally resistant strains can be shown to concentrate streptomycin accumulated by the energy-dependent process above the external concentration in nutrient broth but not in Trypticase soy broth. The energy-dependent accumulation can be saturated in the Str(r) strain of E. coli in nutrient broth, implying limited accumulation sites.
D000225:Adenine / Q000378:metabolism; D000963:Antimetabolites / Q000494:pharmacology; D003470:Culture Media; D004352:Drug Resistance, Microbial; D004926:Escherichia coli / Q000187:drug effects / Q000378:metabolism*; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000378:metabolism*; D012270:Ribosomes / Q000187:drug effects; D013307:Streptomycin / Q000378:metabolism* / Q000494:pharmacology; D013997:Time Factors
D000963:Antimetabolites; D003470:Culture Media; D000225:Adenine; D013307:Streptomycin